Isolation of two variants of native one-chain tissue plasminogen activator, FEBS Letters, vol.78, issue.2, pp.289-292, 1982. ,
DOI : 10.1016/0014-5793(82)80936-8
Equivocal roles of tissue-type plasminogen activator in stroke-induced injury, Trends in Neurosciences, vol.27, issue.3, pp.155-160, 2004. ,
DOI : 10.1016/j.tins.2003.12.011
Human Plasma Proteinase Inhibitors, Annual Review of Biochemistry, vol.52, issue.1, pp.655-709, 1983. ,
DOI : 10.1146/annurev.bi.52.070183.003255
Serpins, Proteinase Inhibitors, pp.403-420, 1986. ,
DOI : 10.1002/047120918X.emb1410
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets., Journal of Clinical Investigation, vol.74, issue.4, pp.1465-1472, 1984. ,
DOI : 10.1172/JCI111559
Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator, Archives of Biochemistry and Biophysics, vol.262, issue.1, pp.199-210, 1988. ,
DOI : 10.1016/0003-9861(88)90182-8
Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin, Biochemistry, vol.26, issue.24, pp.7786-7791, 1987. ,
DOI : 10.1021/bi00398a038
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA., Journal of Clinical Investigation, vol.84, issue.2, pp.647-655, 1989. ,
DOI : 10.1172/JCI114211
Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro, Thromb. Haemost, vol.71, p.124, 1994. ,
A slow clearing, fibrin?specific , PAI?1 resistant variant of t?PA, Thromb. Haemost, vol.70, pp.307-312, 1993. ,
Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1, Blood, vol.79, pp.417-429, 1992. ,
Thrombolysis: newer thrombolytic agents and their role in clinical medicine, Heart, vol.89, issue.11, pp.1358-1362, 2003. ,
DOI : 10.1136/heart.89.11.1358
Plasminogen activators: A comparison, Vascular Pharmacology, vol.44, issue.1, pp.1-9, 2006. ,
DOI : 10.1016/j.vph.2005.09.003
The role of thrombolytic drugs in the management of myocardial infarction: Comparative clinical trials, European Heart Journal, vol.17, issue.suppl F, pp.9-15, 1996. ,
DOI : 10.1093/eurheartj/17.suppl_F.9
Expression of a Novel Chimeric Truncated t-PA in CHO Cells Based on in Silico Experiments, Journal of Biomedicine and Biotechnology, vol.137, issue.6, pp.108-159, 2010. ,
DOI : 10.1023/B:BILE.0000003992.09492.4b
URL : https://hal.archives-ouvertes.fr/pasteur-00821614
Characterization of a modified human tissue plasminogen activator comprising a kringle?2 and a protease domain, J. Biol. Chem, vol.265, pp.5170-5177, 1990. ,
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis, British Journal of Pharmacology, vol.16, issue.suppl., pp.271-276 ,
DOI : 10.1111/j.1476-5381.1996.tb15398.x
Antithrombotic Therapy in Patients With Acute Coronary Syndromes, Archives of Internal Medicine, vol.161, issue.7, pp.937-948, 2001. ,
DOI : 10.1001/archinte.161.7.937
Hepatic clearance of tissue-type plasminogen activator in rats, Thromb. Haemost, vol.54, pp.661-664, 1985. ,
Reteplase in the Treatment of Peripheral Arterial and Venous Occlusions: A Pilot Study, Journal of Vascular and Interventional Radiology, vol.11, issue.7, pp.849-854, 2000. ,
DOI : 10.1016/S1051-0443(07)61799-0
Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1., Proceedings of the National Academy of Sciences, vol.87, issue.9, pp.3530-3533, 1990. ,
DOI : 10.1073/pnas.87.9.3530
Pharmaco-Informatics: Homology Modelling of the Target Protein (GP1, 2) for Ebola Hemorrhagic Fever and Predicting an Ayurvedic Remediation of the Disease, Journal of Proteomics & Bioinformatics, vol.02, issue.07, pp.287-294, 2009. ,
DOI : 10.4172/jpb.1000088
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli, Nature, vol.2, issue.5897, pp.214-221, 1983. ,
DOI : 10.1038/301214a0
Tissue-type plasminogen activator: Characteristics, applications and production technology, Biotechnology Advances, vol.14, issue.3, pp.239-266, 1996. ,
DOI : 10.1016/0734-9750(96)00019-5
Secretion of Active Human Tissue Plasminogen Activator from the Filamentous Fungus Aspergillus Nidulans, Bio/Technology, vol.33, issue.12, pp.1301-1304, 1987. ,
DOI : 10.1084/jem.148.1.223
Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae, Biotechnol. Appl. Biochem, vol.48, pp.55-61, 2007. ,
Protease inhibitors , a DNA construct for the expression of a protease and a process for measuring proteases and/or protease inhibitors, EP0736302), 1996. ,
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION, The Lancet, vol.330, issue.8549, pp.3-9, 1987. ,
DOI : 10.1016/S0140-6736(87)93050-9
Serpin-resistant mutants of human tissue-type plasminogen activator, Nature, vol.339, issue.6227, pp.721-724, 1989. ,
DOI : 10.1038/339721a0
An algorithm for protein secondary structure prediction based on class prediction, "Protein Engineering, Design and Selection", vol.1, issue.4, pp.289-294, 1987. ,
DOI : 10.1093/protein/1.4.289
URL : https://hal.archives-ouvertes.fr/hal-00313814
Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates, Analytical Biochemistry, vol.102, issue.1, pp.196-202, 1980. ,
DOI : 10.1016/0003-2697(80)90338-3
Polymerization site in the .beta. chain of fibrin: mapping of the B.beta.1-55 sequence, Biochemistry, vol.30, issue.1, pp.162-168, 1991. ,
DOI : 10.1021/bi00215a024
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma, Thrombosis Research, vol.31, issue.3, pp.427-436, 1983. ,
DOI : 10.1016/0049-3848(83)90407-3
PAI-1-resistant t-PA: low doses prevent fibrin deposition in rabbits with increased PAI-1 activity, Blood, vol.87, pp.14-19, 1996. ,
Purified type I and type II t, 1989. ,
Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06, Protein Eng, vol.5, pp.22-93, 1992. ,